Skip to main content
. 2020 Feb 7;28(1):65–73. doi: 10.3727/096504019X15656904013079

Figure 1.

Figure 1

FOXD2-AS1 expression is increased, whereas miR-195 expression is inhibited in esophageal squamous cell carcinoma (ESCC) cells and cisplatin-resistant ESCC cells. (A) Quantitative real-time polymerase chain reaction (qRT-PCR) was performed to assess the expression of FOXD2-AS1 in 20 pairs of ESCC specimens and matched surrounding nonmalignant tissues. (B) qRT-PCR was performed to assess the expression of miR-195 in 20 pairs of ESCC specimens and matched surrounding nonmalignant tissues. The results are shown as means ± SEM, n = 20, **p < 0.01 versus tumor specimens. (C) qRT-PCR was performed to assess FOXD2-AS1 expression in normal esophageal cells (HEEC), ESCC cells (TE-1), and cisplatin-resistant ESCC cells (TE-1/DDP). (D) qRT-PCR was used to assess the expression of miR-195 in HEEC cells, TE-1 cells, and TE-1/DDP cells. The results are shown as means ± SEM. **p < 0.01 versus the expression in HEEC cells.